Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 244 participants.
Also called NCT04665284
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 244 participants
- Sponsor
- Registry
-
NCT04665284
-
- Other papers using this trial's data
- Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT04665284. Randomized; no masking; primary purpose treatment. Start 2019-06-01 (actual); primary completion 2020-09-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus
- Acronym
- SAFE-PAK
- Condition
- Type II Diabetes Mellitus
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Usual care group
- Lead sponsor
- Getz Pharma
Record details
- Record id
cardio:ct-nct04665284- Content hash
aef8728bf4eef9e89de5647210d2385bf02e63c5d0a34af321dfe69da1139d64